$AMGN mention timeline

AMGEN. Every tracked FinTwit mention of $AMGN, newest first. 26 mentions since the first on Jun 30, 2025. See the price chart.

May 2026 · 1 mention

May 8
Jacob Plieth — Backing for $ZLAB's DLL3 + DLL3 efforts? $AMGN https://t.co/rRkvNepL11↗

Apr 30
Jacob Plieth — Krystal-10 was the (delayed) confirmatory trial, so does the FDA now rescind Krazati's accelerated approval in colorectal cancer? $BMY $AMGN↗
Apr 28
Adam Feuerstein ✡️ — FDA launches effort with $AZN $AMGN to speed up clinical trials, using AI https://t.co/k4LjxnDLmq via @LizzyLaw_↗
Apr 15
Jacob Plieth — Next, why not run a trial combining Imdelltra + zoci-P + obrixtamig? Any scientific reason not to? $AMGN $ZLAB↗
Apr 1
Jacob Plieth — Ha ha, great April Fool's joke from $ZLAB $AMGN! https://t.co/HlXz61yXa9↗

Mar 18
Jacob Plieth — $MRK's PD-1 x VEGF bispecific reveal, & other key #AACR26 presentations, via @APEXONCO -> https://t.co/ob1eswxCWF $RVMD $AMGN $GILD $BCYC $SDGR↗
Mar 18
Jacob Plieth — $AMGN's likely discontinued anti-CCR8 MAb #AACR26↗
Mar 16
Jacob Plieth — Since my 2024 look at CCR8 a lot has happened: $BMY $GILD $ABBV upsized; $ONC Bayer $ZLAB (& soon $AMGN?) discontinued. @BatirtzeAreitio investigates, via @ApexOnco -> https…↗

Feb 26
Jacob Plieth — $RVMD was collaborating with $TNGX in PRMT5, but now it's working with $BMY (remember that ex MRTX project?). Via @ByMadeleineA @ApexOnco -> https://t.co/mGZjKOiB7p (And $AMGN s…↗
Feb 3
Adam Feuerstein ✡️ — $AMGN Tavneos update. FDA wants it pulled from the market. On January 16, 2026, the U.S. Food and Drug Administration (FDA) requested that ChemoCentryx voluntarily withdraw TAVNE…↗
Feb 2
Adam Feuerstein ✡️ — Another OX40 update, and it's not good. On an analyst call Sunday, Kyowa Kirin disclosed a case of Karposi's sarcoma with rocatinlimab in a "high risk" patient, according to a Je…↗

Jan 30
Adam Feuerstein ✡️ — And now $AMGN returns its OX40 drug candidate rocatinlimab to Kyowa.↗
Jan 30
Adam Feuerstein ✡️ — What's this about? EMA re-reviewing $AMGN Tavneos due to "data integrity" issues in study that supported approval. https://t.co/lg9eh7qSmJ↗
Jan 23
Adam Feuerstein ✡️ — Leerink's David Risinger on the $SNY amlitelimab Karposi's sarcoma case: "As a result, we see risk of a potential black box warning on amlitelimab’s label." Would be same for $A…↗
Jan 23
Adam Feuerstein ✡️ — Perhaps I am over-reacting, but doesn't the reported case of Kaposi's sarcoma in the $SNY amlitelimab atopic dermatitis study basically end any hope for the entire OX40 drug class?…

Dec 22
Jacob Plieth — $AZN follows $LLY $PFE $AMGN $ONC & $ALPMF into pan-KRAS, but should it be looking more to pan-RAS approaches like $RVMD & $ERAS? Via @ApexOnco -> https://t.co/MioOWziu…↗
Dec 22
Jacob Plieth — @NotGenentech @bioinvestor24 Here's a list of just the clinical pan-RAS & pan-KRAS assets from Oncologypipeline $RVMD $LLY $ONC $RHHBY $PFE $ERAS $AZN $AMGN $ALPMF https://t.co…↗

Nov 8
Adam Feuerstein ✡️ — #AHA25 reporting all weekend Amgen’s $AMGN cholesterol shot prevented first heart attacks and strokes, more detailed data affirm https://t.co/1RX6TrfU6l via @cooney_liz↗

Sep 24
Jacob Plieth — Apparently #SITC25 is hosting a webinar on development of anti-CCR8 MAbs - mechanisms & clinical results. 22 Oct 2025 $CHRS $BMY $ABBV $RHHBY $AMGN $GILD $BGNE $FGEN $BNTX↗
Sep 18
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter: - $SGMO 's Fabry therapy partner search looks futile - Geoff Porges is back on Wall Street, taking a banking role at Lazard - Don't get r…↗
Sep 4
Jacob Plieth — But it's not clear how bad the OS decline has been from interim -> final analysis. $AMGN Paul Burton @ W Fargo: "at a recently completed final analysis the magnitude of the surv…↗
Sep 4
Jacob Plieth

Jun 30
Jacob Plieth — $AMGN Fortitude-101 study of bemarituzumab (ex $FPRX) + chemo is stat sig "& clinically meaningful" for OS vs chemo alone. FGFR2b overexpression (≥10% @ IHC 2+/3+) was enrolmen…↗